← Back to guidelines
Cardiology6 papers

Acquired long QT syndrome

Last edited: 4/22/2026

Overview

Acquired long QT syndrome (aLQTS) is characterized by prolonged QT intervals on the electrocardiogram (ECG) due to non-genetic factors, often leading to increased risk of torsade de pointes and sudden cardiac events 1.

Diagnosis

  • Key diagnostic criterion: Prolonged QT interval on ECG (QTc > 440 ms in men, > 460 ms in women) 1.
  • Consider clinical triggers such as electrolyte imbalances (e.g., hypokalemia), certain medications, and underlying conditions like structural heart disease 2.
  • Evaluate for reversible causes including drug toxicity, metabolic disturbances, and acute illness 2.
  • Management

  • First-line treatments: Correct underlying causes (e.g., electrolyte imbalances, discontinuation of offending drugs) 2.
  • Adjunctive treatments: Beta-blockers are commonly used to reduce the risk of arrhythmias 2.
  • Device therapy: Implantable cardioverter defibrillators (ICD) recommended for secondary prevention in patients with prior cardiac arrest due to aLQTS 2 (Evidence: Moderate).
  • Special Populations

  • Comorbidities: Patients with cancer, chronic kidney disease, and structural heart diseases (e.g., ischemic heart disease, dilated cardiomyopathy) have increased mortality risk 1.
  • No specific guidance provided for pregnancy, pediatrics, or elderly populations in the given abstracts.
  • Key Recommendations

  • Identify and correct reversible causes such as electrolyte imbalances and drug-induced QT prolongation (Evidence: Moderate) 2.
  • Use beta-blockers as first-line pharmacological therapy to mitigate arrhythmia risk 2 (Evidence: Moderate).
  • Consider implantation of an ICD for secondary prevention in patients with a history of cardiac arrest due to aLQTS 2 (Evidence: Moderate).
  • References

    1 Chen C, Zhou J, Yu H, Zhang Q, Gao L, Yin X et al.. Identification of important risk factors for all-cause mortality of acquired long QT syndrome patients using random survival forests and non-negative matrix factorization. Heart rhythm 2021. link 2 Mönnig G, Köbe J, Löher A, Wasmer K, Milberg P, Zellerhoff S et al.. Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2012. link

    Original source

    1. [1]
    2. [2]
      Role of implantable cardioverter defibrillator therapy in patients with acquired long QT syndrome: a long-term follow-up.Mönnig G, Köbe J, Löher A, Wasmer K, Milberg P, Zellerhoff S et al. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2012)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG